ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
- 1 May 2014
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 84 (2), 121-126
- https://doi.org/10.1016/j.lungcan.2014.02.007
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never SmokersPLOS ONE, 2011
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant KinasesJournal of Clinical Oncology, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007